Juergen Utz, Ph.D., Gerhard Noessner, Ph.D., and Juergen Bank, Ph.D., of Fareva Excella discuss how developing robust processes from the outset by building broad and fundamental process knowledge minimizes future validation and revalidation work for drug substance manufacturing.
.svg)
